1817-73-8

Applied Filters:

Keyword:'1817-73-8'

Showing 1-1 of 1 result for "1817-73-8" within Papers

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Maheshi N Ramasamy et al.

Lancet (London, England), 396(10267), 1979-1993 (2020-11-23)

Older adults (aged ≥70 years) are at increased risk of severe disease and death if they develop COVID-19 and are therefore a priority for immunisation should an efficacious vaccine be developed. Immunogenicity of vaccines is often worse in older adults

Page 1 of 1